Gunderson Dettmer represented Carbon Biosciences on the deal. Carbon Biosciences, a developer of novel parvovirus-derived gene therapies, announced its emergence from stealth mode and the closing of...
You must be a Standard 1 Year member to access this content.
Davis Polk advised GSK plc on the deal while Gunderson Dettmer represented Affinivax. GSK plc announced its acquisition of Affinivax, Inc. for a $2.1 billion upfront...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised Remix Therapeutics on the deal. Remix Therapeutics, a Massachusetts-based biotech company, announced its $70 million Series B financing which included participation from Surveyor, Foresite...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Remix Therapeutics on the deal. Remix Therapeutics, a Massachusetts-based biotech company, announced its collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised HotSpot Therapeutics on the deal. HotSpot Therapeutics Inc., a biotechnology company, announced a strategic collaboration agreement with Caris Life...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Immunitas Therapeutics on the deal. Immunitas Therapeutics, an immuno-oncology biotech company, announced its $58 million Series B financing round. The round...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Lyndra Therapeutics on the deal. Lyndra Therapeutics, a developer of orally administered steady-state release pills, announced its $60.5...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised ImmuneID on the deal. ImmuneID, Inc., a precision immunology company employing a proprietary platform to identify and...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Interline Therapeutics on the deal. Interline Therapeutics, a data science and healthcare company, announced its $92 million Series...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Pyxis Oncology on the deal. Pyxis Oncology (“Pyxis” or the “Company”) announced the closing of a $152 million...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Boston Pharma on the deal. Boston Pharma, a clinical stage biopharmaceutical company developing differentiated therapeutics, announced its strategic...
You must be a Standard 1 Year member to access this content.
